Enterosys has the unique combination of the scientific expertise, R&D skills and state-of-the-art technologies to become a leading preclinical CRO in its market.
With its technological lead in the investigation of the digestive sphere, Enterosys’ objective is to become the reference player in the field of the gut, the gut-brain axis and the gut-organ.
With such a line of investigation, Enterosys aims to become a key partner in research on neurodegenerative, metabolic and intestinal diseases.”
Jean-Christophe Malrieu is an entrepreneur with a Master’s degree in Business Management from the University of Paris Dauphine and a Bachelor’s degree in Economics. He had a long international experience in multinational companies such as Unilever (18 years) and Shiseido (4 years) before joining SME companies as CEO. He has extensive experience in innovation and development, marketing and sales, finance, export, food and beauty and, for 12 years, in healthcare. In 2010, he became president and CEO of Phythea, a French nutraceutical leader specializing in joint and women’s health. In early 2017, he co-founded A-Mansia Biotech SA in Belgium, a spin-off from Wageningen University and UC Leuven aiming to fight obesity and T2D with Akkermansia muciniphila, a key species of human gut microbiota discovered in 2006 by the company’s founders. In 2018, he raised €25 million to fund the development of A-Mansia, including €18 million in a Series A round. In December 2021, he decided to join ENTEROSYS as CEO.